[Form 4] Mayville Engineering Company, Inc. Insider Trading Activity
Rachele M. Lehr, Chief Financial Officer of Mayville Engineering Company (MEC), purchased 1,400 shares of MEC common stock on 08/08/2025 at $14.08 per share, increasing her direct holdings to 20,761 shares. The filing also reports that Ms. Lehr directly beneficially owns restricted stock units (17,120 and 17,422) that vest in staged increments (one grant vests one-third on March 15 of 2025, 2026 and 2027; the other vests one-third on March 15 of 2026, 2027 and 2028).
The report shows a stock option covering 24,814 shares with an exercise price of $14.12 and an expiration date of 02/28/2033; the option vesting schedule was 50% on 02/28/2024 and 50% on 02/28/2025. The transaction reported is a direct purchase and the filing lists the post-transaction and derivative holdings explicitly.
- CFO executed a direct purchase of 1,400 shares, increasing her reported direct ownership to 20,761 shares.
- Executive holds RSUs and stock options with disclosed vesting schedules and exercise price, aligning compensation with future performance.
- None.
Insights
TL;DR: CFO made a small direct purchase (1,400 shares) and holds RSUs and options, all reported on Form 4.
The purchase on 08/08/2025 at $14.08 equals approximately $19,712 in cash outlay based on the reported price, raising direct common stock holdings to 20,761 shares. The filing separately discloses two restricted stock unit grants (17,120 and 17,422 RSUs) with clear multi-year vesting schedules and a stock option for 24,814 shares at a $14.12 exercise price expiring 02/28/2033. From a reporting and disclosure perspective, the form is complete and provides the core metrics investors and compliance teams track: transaction date, price, post-transaction ownership, and derivative terms.
TL;DR: The Form 4 documents routine insider compensation instruments and a modest open-market purchase by the CFO.
The filing lists both compensation-related equity (two RSU grants with staged vesting and an option grant with specified exercise price and expiration) and a contemporaneous direct purchase of 1,400 shares. Vesting schedules and option terms are spelled out, supporting transparency about executive alignment with shareholder value. The filing does not present any regulatory exceptions or irregularities; materiality for investors depends on company size and total outstanding shares, which are not provided in this document.